´ëÇÑ°£¾ÏÇÐȸ Á¦17Â÷ Á¤±âÇмú´ëȸ-Beating HCC Together : 2023-03-17±³À°ÀÏÀÚ : 2023-03-17
±³À°Àå¼Ò : ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë
±³À°ÁÖÁ¦ :
(¿ÀÇÁ¶óÀÎ) ´ëÇÑ°£¾ÏÇÐȸ Á¦17Â÷ Á¤±âÇмú´ëȸ-Beating HCC TogetherÁÖÃÖ±â°ü : ´ëÇÑ°£¾ÏÇÐȸ
´ã´çÀÚ : ÀÌÁøÈ Â÷Àå
¿¬¶ôó : 02-373-1005
À̸ÞÀÏ :
klca@hbni.co.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°ú
Âü¼®¿¹»óÀοø : 400¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 10 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 60,000¿ø
ºñ°í »çÀüµî·Ï : Æò»ýȸ¿øÁ¤È¸¿ø-4¸¸¿ø, ºñȸ¿ø-5¸¸¿ø, ÀüÀÓÀÇÀü°øÀDZºÀÇ°ü°£È£»ç-2¸¸¿øÇöÀåµî·Ï : Æò»ýȸ¿øÁ¤È¸¿ø-5¸¸¿ø, ºñȸ¿ø-6¸¸¿ø, ÀüÀÓÀÇÀü°øÀDZºÀÇ°ü°£È£»ç-3¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 08:45~09:00 Noncontrast MRI with Diffusion-Weighted Imaging for Detecting HCC À̵¿È£(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 09:00~09:15 Tissue Acquisition for the Accurate Diagnosis of HCC: Surgeon ÀÌÀç±Ù(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 09:15~09:30 Digitial Pathology and AI for the Diagnosis of HCC À̼ºÇÐ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 09:30~09:45 Novel Biomarkers for Early Diagnosis of HCC Á¤½Â¿ø(¼øõÇâÀÇ´ë)
ÈÞ½Ä 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 09:45~09:55 Coffee Break .(.)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 09:55~10:25 Early Mechanism of Liver Carcinogenesis Jessica Zucman-Rossi(ILCA)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 10:25~10:45 Challenges and Opportunities of Combining Immunotherapy with Locoregional Therapies Bruno Sangro(ILCA)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 10:45~11:05 Comparison of Locoregional and Systemic Treatment in Eastern and Western Guidelines Joong-Won Park(KLCA)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 11:05~11:25 Stratification for Systemic Therapy – Are We Making Progress? Tim Meyer (ILCA)(ILCA)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 11:25~11:45 Image Guided Ablation of Early HCC: Up to Date Jeong Min Lee (KLCA)(KLCA)
±âŸ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 11:45~12:45 Lunch Break & °¨»çÆÐ Àü´Þ½Ä ¹× ±¹¾Ç°ø¿¬ .(.)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 12:45~13:25 2023 KLCA Practical Guidance of TACE: Expert Consensus ÀÌÀÎÁØ(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 13:25~13:55 Strategical Application of Radiotherapy for Advanced HCC in the Immunotherapy Era ¼ºÁø½Ç(¿¬¼¼ÀÇ´ë)
ÈÞ½Ä 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 13:55~14:05 Coffee Break .(.)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 14:05~14:20 Various Ablation Techniques for Treatment of HCC À̹οì(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 14:20~14:35 Extended Application of TAREs and Interventional Therapies for Intermediate HCC À̺´Âù(Àü³²ÀÇ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 14:35~14:50 Recent Advances of Surgical Resection and LT ¹®´öº¹(¿ï»êÀÇ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 14:50~15:05 New Technologies of Radiotherapy on HCC Treatment ¹ÚÈñö(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 15:05~15:20 Immune-Based Therapies for HCC ÀÌÁ¤ÈÆ(¼¿ïÀÇ´ë)
±âŸ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 15:20~16:20 Poster Presentation .(.)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 16:20~16:35 Advanced AI in the Prediction of Clinical Outcomes of HCC ÀÓ¼±¿µ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 16:35~16:50 Biomarker-Based Prediction of Clinical Outcomes in HCC ¼ºÇʼö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 16:50~17:05 Updates of Imaging Features Related with Prognosis of HCC ¼ÛÁö¼ö(ÀüºÏÀÇ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room1 17:05~17:20 Pathological Classification for Predicting HCC Prognosis ÀÌÇý¿ø(°è¸íÀÇ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room2 08:45~09:05 °£¾Ï¿¡¼ 2Â÷ Ç×¾ÏÄ¡·áÀÇ ±Þ¿©±âÁØ °³¼± ÀÌÇѾÆ(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room2 09:05~09:30 º¸ÇèÀǾàÇ° °ü¸®Á¦µµ: ºñ¿ë-È¿°úºÐ¼®À» Áß½ÉÀ¸·Î ÀÌÇѱæ(¾ÆÁÖ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room2 09:30~09:55 Ç×¾ÏÁ¦ ±Þ¿© µîÀç¿Í ±Þ¿© ±âÁØ ÀåÁØÈ£(°Ç°º¸Çè½É»çÆò°¡¿ø)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room2 14:05~14:20 Indication of Hepatic Resection: Hepatologist View Á¶ÁÖ¿¬(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room2 14:20~14:40 Expanded Indication for Hepatic Resection ÃÖ¿µ·Ï(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room2 14:40~15:00 Peri-op Considerations after Transarterial or Locoregional Therapy ¹Ú¿µ¸ñ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room2 15:00~15:20 »õ·Î¿î ¼ö¼ú ±â¹ý¿¡ ´ëÇÑ ¼Ò°³: 3D Reconstruction, ICG Fluorescent Image ±èÁöÈÆ(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room2 15:20~15:35 °£¾Ï ¼ö¼ú ÈÄ °£È£°ü¸® À±Áö¼±(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room2 15:35~15:50 TACE ¹× RFA µî °£¾Ï ½Ã¼ú ÈÄ °£È£ °ü¸® ¼±Á¦ÀÎ(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room2 15:50~16:05 °£¾Ï ȯÀÚÀÇ ¿µ¾ç°ü¸® ±èÈñ¾ð(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room2 16:05~16:20 °£¾Ï ȯÀÚÀÇ ÅëÁõ °ü¸® À¯½ÅÇý(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room2 16:20~16:35 Pre-and Post Procedural Evaluation for Transarterial Therapy Á¶¿µÀ±(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room2 16:35~16:55 Indication and Differences between TACE, DEB-TACE, and TARE ±Ç·Á¹Î(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room2 16:55~17:05 Chemotherapeutic Agents in TACE ÃÖÁø¿ì(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03-17 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5F ±×·£µåº¼·ë Room2 17:05~17:20 How to Choose the Best Modality for Transarterial Therapy – Case Based Çöµ¿È£(¼º±Õ°üÀÇ´ë)